Peripheral nerve tumors: management strategies and molecular insights

被引:65
作者
Bhattacharyya, AK
Perrin, R
Guha, A
机构
[1] Toronto Western Hosp, Univ Hlth Network, Dept Neurosurg, Div Neurosurg, Toronto, ON M5T 2S8, Canada
[2] Toronto Western Hosp, Univ Hlth Network, Dept Surg, Toronto, ON M5T 2S8, Canada
[3] Toronto Western Hosp, Univ Hlth Network, Alan & Susan Hudson Chair Neurooncol, Toronto, ON M5T 2S8, Canada
[4] Univ Toronto, Hosp Sick Children, Res Inst, Arthur & Sonia Labatts Brain Tumor Ctr, Toronto, ON, Canada
关键词
experimental therapies; malignant peripheral nerve sheath tumor (MPNST); neurofibromatosis (NF); peripheral nerve tumor (PNT); signaling;
D O I
10.1023/B:NEON.0000041891.39474.cb
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Because of its relative rarity and a wide variety of clinical manifestations, peripheral nerve tumors (PNTs) often present to specialists from widely different disciplines, thus often resulting in delayed diagnosis and a non-cohesive pattern of management. Critical appraisal of the history and physical examination followed by radiological investigations, by experienced medical personnel, ultimately suggests that the extremity mass is perhaps a PNT, rather than the wide variety and more common soft tissue tumors. Included in this appraisal is a search for a pre-disposition syndrome, the most common of which are neurobromatosis-1 and -2 (NF1, NF2) and schwannomatosis, which may require life-long careful follow up. Intra-operative and post-operative management decisions in a multidisciplinary manner with knowledge of the biological, pathological and clinical behavior of the PNT, is of utmost importance. In the context of pre-disposition syndromes, where multiple tumors may exist along with other nervous system lesions, molecular biological insights and hopefully the biological therapies that stem from this knowledge are of interest. In this article the spectrum of PNTs and their management protocols, including the algorithm for treatment of malignant PNTs advocated by our institute, are presented and currently available genetic insights and probable role of experimental therapies are briefly reviewed.
引用
收藏
页码:335 / 349
页数:15
相关论文
共 61 条
[31]  
Korf BR, 1999, AM J MED GENET, V89, P31, DOI 10.1002/(SICI)1096-8628(19990326)89:1<31::AID-AJMG7>3.0.CO
[32]  
2-W
[33]  
KRUEGER W, 1979, AM J SURG, V138, P517, DOI 10.1016/0002-9610(79)90411-2
[34]  
Lakkis MM, 2000, J NEUROSCI RES, V62, P755, DOI 10.1002/1097-4547(20001215)62:6<755::AID-JNR1>3.3.CO
[35]  
2-N
[36]  
LEQUANG C, 1989, HAND CLIN, V5, P23
[37]   GENOMIC ORGANIZATION OF THE NEUROFIBROMATOSIS-1 GENE (NF1) [J].
LI, Y ;
OCONNELL, P ;
BREIDENBACH, HH ;
CAWTHON, R ;
STEVENS, J ;
XU, GF ;
NEIL, S ;
ROBERTSON, M ;
WHITE, R ;
VISKOCHIL, D .
GENOMICS, 1995, 25 (01) :9-18
[38]   NEUROFIBROMATOSIS-2 - (BILATERAL ACOUSTIC NEUROFIBROMATOSIS) [J].
MARTUZA, RL ;
ELDRIDGE, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (11) :684-688
[39]   PALISADED ENCAPSULATED NEUROMA (SOLITARY CIRCUMSCRIBED NEUROMA) - A CLINICOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY [J].
MEGAHED, M .
AMERICAN JOURNAL OF DERMATOPATHOLOGY, 1994, 16 (02) :120-125
[40]   CHROMOSOME-17P DELETIONS AND P53-GENE MUTATIONS ASSOCIATED WITH THE FORMATION OF MALIGNANT NEUROFIBROSARCOMAS IN VONRECKLINGHAUSEN NEUROFIBROMATOSIS [J].
MENON, AG ;
ANDERSON, KM ;
RICCARDI, VM ;
CHUNG, RY ;
WHALEY, JM ;
YANDELL, DW ;
FARMER, GE ;
FREIMAN, RN ;
LEE, JK ;
LI, FP ;
BARKER, DF ;
LEDBETTER, DH ;
KLEIDER, A ;
MARTUZA, RL ;
GUSELLA, JF ;
SEIZINGER, BR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (14) :5435-5439